Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Acute Sinusitis Market size was valued at USD 2.4 billion in 2024 and is set to exceed USD 6 billion by 2037, registering over 7.3% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of acute sinusitis is evaluated at USD 2.55 billion.
The growth of the market can be attributed to the increasing cases of acute sinusitis backed by unhealthy lifestyle, and habits, such as, smoking. Around 25-40 out of every 1000 individual suffer from acute sinusitis, every year, globally. It is more common in adults that children. Chronic sinusitis affects 12-15% of the population. Acute sinus can be caused by bacterial, viral, or fungal infections, or due to the presence of polyps and nasal tumors. It causes extreme discomfort, headache, breathing issues, cough, and nasal congestion, which increases the demand for effective treatment to provide immediate relief as well as long term cure. The increasing demand for better treatment solutions for acute sinusitis is estimated to boost the market growth.
Acute Sinusitis Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Cases of Sinusitis Globally
- Rising Demand for Fast Relief Treatment Solutions for Sinus
Challenges
- Circulation of Generic Drugs in the Market
Acute Sinusitis Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.3% |
|
Base Year Market Size (2024) |
USD 2.4 billion |
|
Forecast Year Market Size (2037) |
USD 6 billion |
|
Regional Scope |
|
Acute Sinusitis Segmentation
The global acute sinusitis market is segmented by diagnosis into nasal endoscopy, imaging test, and others, out of which, the imaging test segment is anticipated to hold a notable share in the market during the forecast period on account of high accuracy of imaging test, such as, CT scan, and MRI. The acute sinusitis market is segmented by treatment into saline nasal spray, corticosteroid spray, oral decongestant therapy, sinus dilation devices, medications, and surgery. Out of these, the saline nasal spray segment is anticipated to garner a significant share during the forecast period owing to their easy availability at drug stores, and affordable prices. On the other hand, the medication segment is also estimated to gain significant share, on the back of its effectiveness in relieving acute sinus in a short time.
|
By Diagnosis |
|
|
By Treatment |
|
|
By End-User
|
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAcute Sinusitis Industry - Regional Synopsis
North America Market Statistics
Regionally, the global acute sinusitis market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America industry is anticipated to account for largest revenue share by 2037, on the back of high prevalence of sinusitis in the region. Over 28 million adults were diagnosed with sinusitis in the United States, in 2020. Moreover, the increasing government investment in healthcare sector and favorable medical reimbursement policies are estimated to boost the regional market growth. According to the World Health Organization (WHO), as of 2018, 16.416 % of the GDP was spent on the healthcare sector in North America.
APAC Market Analysis
The acute sinusitis market in the Asia Pacific is estimated to witness notable growth over the forecast period accounting to the increasing cases of respiratory diseases, due to the increasing pollution in major cities, such as, Shanghai, Hotan, Delhi, Kathmandu, and Kabul, among others. Moreover, increasing investment in public healthcare system is estimated to boost the market growth in the region.
Companies Dominating the Acute Sinusitis Landscape
- F. Hoffmann-La Roche Ltd
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Cerecor, Inc.
- Bausch Health Companies Inc.
- Boehringer Ingelheim International GmbH
- AbbVie Inc.
- Amgen Inc.
- Novartis AG
- Bayer AG
- Progenity, Inc.
In the News
· August 6, 2020: Novartis AG announced the approval of Xolair as an add-on therapy with intranasal corticosteroids for the treatment of rhinosinusitis with nasal polyps.
Author Credits: Radhika Pawar
- Report ID: 3117
- Published Date: Dec 26, 2024
- Report Format: PDF, PPT
